Metabolic Disease Therapies
October 15 – 17, 2017, San Diego, CA, USA
According to the first WHO Global report on diabetes, the incidence of type 2 diabetes, and its consequent metabolic sequelae, has essentially quadrupled since 1980 to 422 million adults worldwide. The underlying causes are complex though generally attributed to an alarming rise in obesity. There is an urgent need for effective therapies other than lifestyle changes that do not negatively impact cardiovascular health. Recent clinical reports of the safety and efficacy of the SGLT2 inhibitors, GLP-1 based agonism, and PCSK9 inhibitors, to name a few, have generated much hope and excitement. However, it is crucial that metabolic therapeutic research stays ahead of the curve. This meeting will address cutting-edge therapeutic pathways and key conceptual advances in targeting diabetes, obesity, fatty liver, and cardiovascular complications. Additionally, there will be a particular focus on novel technologies and ways in which they can be harnessed to combat metabolic complications.
- Metabolic precision medicine
- Translating therapeutics for metabolic diseases
- Integrated energy metabolism
Abstract submission deadline June 30, 2017